Literature DB >> 9276242

Effect of treatment on contagiousness of patients with active pulmonary tuberculosis.

D Menzies1.   

Abstract

In view of the important consequences with regard to policies for respiratory isolation of hospitalized patients with active tuberculosis, the duration of contagiousness after initiation of effective therapy was reviewed. All relevant English-language literature was reviewed to identify in vitro, animal experimental, and epidemiological evidence regarding contagiousness of patients with active tuberculosis after initiation of therapy. Based on in vitro evidence of numbers of tubercle bacilli initially present and rapidity of reduction-with therapy, it can be predicted that patients whose respiratory secretions are initially smear-negative but culture-positive should no longer have viable bacilli detectable by culture within 2 weeks. Based on the same evidence, it can be predicted that, after 2 weeks of therapy, almost all smear-positive patients will remain culture-positive, and more than one half will remain smear-positive. There are few epidemiological studies of this issue, most of which have had major methodological weaknesses. None of the results from these studies can be considered relevant to the hospital environment, where the majority of workers are uninfected and patients are potentially immunocompromised. Animal and in vitro evidence suggest that patients with active tuberculosis remain contagious at least 2 weeks after the initiation of therapy. Patients with smear-positive disease are likely to be contagious much longer. There is no relevant and valid epidemiological evidence regarding this issue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276242     DOI: 10.1086/647678

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  19 in total

Review 1.  Tuberculosis: 10. Prevention.

Authors:  D Menzies; T N Tannenbaum; J M FitzGerald
Journal:  CMAJ       Date:  1999-09-21       Impact factor: 8.262

Review 2.  Tuberculosis: 11. Nosocomial disease.

Authors:  K Schwartzman; D Menzies
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

Review 3.  Medical management of drug-sensitive active thoracic tuberculosis: the work-up, radiographic findings and treatment.

Authors:  Jared Eddy; Taimur Khan; Frank Schembri
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

4.  The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection.

Authors:  David W Dowdy; Richard E Chaisson
Journal:  Bull World Health Organ       Date:  2009-04       Impact factor: 9.408

5.  Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy.

Authors:  Sean P Fitzwater; Luz Caviedes; Robert H Gilman; Jorge Coronel; Doris LaChira; Cayo Salazar; Juan Carlos Saravia; Krishna Reddy; Jon S Friedland; David A J Moore
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

Review 6.  GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs.

Authors:  Grant Theron; Jonny Peter; Marty Richardson; Rob Warren; Keertan Dheda; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2016-09-08

7.  Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis.

Authors:  A S Dharmadhikari; M Mphahlele; K Venter; A Stoltz; R Mathebula; T Masotla; M van der Walt; M Pagano; P Jensen; E Nardell
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

8.  Infection control and paediatric tuberculosis: A practical guide for the practicing paediatrician.

Authors:  Anne Matlow; Maryanne Robb; Carol Goldman
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

9.  Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis.

Authors:  Kevin P Fennelly; Edward C Jones-López; Irene Ayakaka; Soyeon Kim; Harriet Menyha; Bruce Kirenga; Christopher Muchwa; Moses Joloba; Scott Dryden-Peterson; Nancy Reilly; Alphonse Okwera; Alison M Elliott; Peter G Smith; Roy D Mugerwa; Kathleen D Eisenach; Jerrold J Ellner
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405

10.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.